San Diego, CA -- (SBWIRE) -- 10/02/2015 -- An investigation for shareholders in shares of Synergetics USA Inc (NASDAQ:SURG), was announced concerning the takeover of Synergetics USA Inc. by Valeant Pharmaceuticals International.

Investors who purchased shares of Synergetics USA Inc (NASDAQ:SURG) and currently hold any of those NASDAQ:SURG shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain officers and directors of Synergetics USA Inc breached their fiduciary duties owed to NASDAQ:SURG investors in connection with the proposed acquisition.

On September 2, 2015, Synergetics USA Inc (NASDAQ:SURG) and Valeant Pharmaceuticals International ("Valeant"), a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX), announced that they have entered into an agreement under which Valeant will acquire Synergetics USA Inc (NASDAQ:SURG) for $6.50 per share in cash. In addition to the upfront cash payment, Synergetics stockholders will receive additional cash payments of up to $1.00 per share if specified sales milestones are achieved following the closing.

However, the investigation concerns whether the offer is unfair to NASDAQ:SURG stockholders. More specifically, the investigation concerns whether the Synergetics Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

On Oct. 1 2015, NASDAQ:SURG shares closed at $6.56 per share.

Those who are current investors in NASDAQ:SURG shares have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com